Tejara Capital Ltd Has $2.81 Million Holdings in Cardiol Therapeutics Inc. $CRDL

Tejara Capital Ltd decreased its position in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 19.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,630,122 shares of the company’s stock after selling 635,697 shares during the quarter. Cardiol Therapeutics accounts for approximately 1.5% of Tejara Capital Ltd’s investment portfolio, making the stock its 24th largest position. Tejara Capital Ltd’s holdings in Cardiol Therapeutics were worth $2,814,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in CRDL. Sheets Smith Investment Management bought a new position in Cardiol Therapeutics in the third quarter valued at approximately $152,000. Bank of America Corp DE boosted its holdings in shares of Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock valued at $36,000 after purchasing an additional 15,255 shares in the last quarter. Finally, Thompson Davis & CO. Inc. acquired a new stake in shares of Cardiol Therapeutics in the 2nd quarter valued at $39,000. Institutional investors own 12.49% of the company’s stock.

Wall Street Analysts Forecast Growth

CRDL has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a report on Monday, December 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Cardiol Therapeutics Trading Down 3.0%

NASDAQ CRDL opened at $0.95 on Friday. The company has a market cap of $106.17 million, a price-to-earnings ratio of -3.17 and a beta of 1.04. Cardiol Therapeutics Inc. has a twelve month low of $0.77 and a twelve month high of $1.59. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average is $1.01 and its 200 day moving average is $1.09.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its earnings results on Thursday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). As a group, sell-side analysts expect that Cardiol Therapeutics Inc. will post -0.33 EPS for the current fiscal year.

Cardiol Therapeutics Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.